Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
Cell Reports · 2023
DOI: 10.1016/j.celrep.2023.112538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023. Verfasst von Jinhyuk Bhin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; Division of Molecular Carcino…. Hauptthemen laut MEDLINE: Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Cancer League, Swiss National Science Foundation, KWF Kankerbestrijding.
Abstract (Originalsprache)
BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis), but they eventually acquire resistance. Preclinical studies yielded several PARPi resistance mechanisms that do not involve BRCA1/2 reactivation, but their relevance in the clinic remains elusive. To investigate which BRCA1/2-independent mechanisms drive spontaneous resistance in vivo, we combine molecular profiling with functional analysis of HR of matched PARPi-naive and PARPi-resistant mouse mammary tumors harboring large intragenic deletions that prevent reactivation of BRCA1/2. We observe restoration of HR in 62% of PARPi-resistant BRCA1-deficient tumors but none in the PARPi-resistant BRCA2-deficient tumors. Moreover, we find that 53BP1 loss is the prevalent resistance mechanism in HR-proficient BRCA1-deficient tumors, whereas resistance in BRCA2-deficient tumors is mainly induced by PARG loss. Furthermore, combined multi-omics analysis identifies additional genes and pathways potentially involved in modulating PARPi response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, 1066CX Am…
- Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
- Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; OncoProteomics Laboratory, Department Medical Oncology, Amsterdam UMC, 1081HV Amsterdam, the Nether…
- OncoProteomics Laboratory, Department Medical Oncology, Amsterdam UMC, 1081HV Amsterdam, the Netherlands.
- Division of Cell Biology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
- Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical…
Förderung
- Swiss Cancer League
- Swiss National Science Foundation
- KWF Kankerbestrijding
- Wilhelm Sander Foundation
- Oncode Institute
- European Research Council
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Bhin, J., Paes Dias, M., Gogola, E., Rolfs, F., Piersma, S. R., de Bruijn, R., de Ruiter, J. R., van den Broek, B., Duarte, A. A., Sol, W., van der Heijden, I., Andronikou, C., Kaiponen, T. S., Bakker, L., Lieftink, C., Morris, B., Beijersbergen, R. L., van de Ven, M., Jimenez, C. R., …, & Jonkers, J. (2023). Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors. Cell Reports. https://doi.org/10.1016/j.celrep.2023.112538
Vancouver
Bhin J, Paes Dias M, Gogola E, Rolfs F, Piersma SR, de Bruijn R, et al. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors. Cell Reports. 2023. doi:10.1016/j.celrep.2023.112538
BibTeX
@article{Bhin2023,
author = {Bhin, Jinhyuk and Paes Dias, Mariana and Gogola, Ewa and Rolfs, Frank and Piersma, Sander R and de Bruijn, Roebi and de Ruiter, Julian R and van den Broek, Bram and Duarte, Alexandra A and Sol, Wendy and van der Heijden, Ingrid and Andronikou, Christina and Kaiponen, Taina S and Bakker, Lara and Lieftink, Cor and Morris, Ben and Beijersbergen, Roderick L and van de Ven, Marieke and Jimenez, Connie R and Wessels, Lodewyk F A and Rottenberg, Sven and Jonkers, Jos},
title = {Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors},
journal = {Cell Reports},
year = {2023},
doi = {10.1016/j.celrep.2023.112538}
}
EUVIMED